US-based gene-editing technology developer Inscripta closed a $55.5m series C round on Wednesday co-led by Mérieux Développement, the investment arm of healthcare technology provider Institut Mérieux.
Venture capital firm Paladin Capital co-led the round, which also featured Venrock, Foresite, MLS Capital and NanoDimension.
Founded in 2015 as Muse Biotechnology, Inscripta’s offering enables researchers to engineer cells by using a suite of gene-editing tools including instruments, reagents and software.
The technology is based on research by Ryan Gill, Slade professor of…